Exhibit 99.1


/C O R R E C T I O N -- PHC, Inc. /
Wednesday February 15, 10:04 am ET

In the news  release,  PHC, Inc. (OTC  Bulletin  Board:  PIHC - News)  Announces
Fiscal 2006 Second Quarter Financial Results, issued yesterday, Feb. 14, by PHC,
Inc. over PR Newswire,  we are advised by a  representative  of the company that
the second  paragraph,  second sentence should read,  "24.7 percent  increase in
patient  days"  rather than "7.9  percent  increase"  and the second  paragraph,
fourth sentence should read "tobacco  cessation services which began in November
of 2005 for a major  government  contractor"  rather  than "for a United  States
Government  Agency"  as  originally  issued  inadvertently.  Complete  corrected
release follows:

                 PHC, INC. ANNOUNCES FISCAL 2006 SECOND QUARTER
                                FINANCIAL RESULTS


FOR IMMEDIATE RELEASE

Company Contact:           Investor Relations Contact:
- ---------------            --------------------------
PHC, Inc.                  Hayden Communications, Inc.
Bruce A. Shear             Matthew Hayden
978-536-2777               843-272-4653

>>       Q2FY06 REVENUE OF $8.7 MILLION VS. $8.1 MILLION IN Q2FY05
>>       Q2FY06 EPS OF $.02 VS. $.02 IN Q2 FY05
>>       Q2FY06 NON-PATIENT OPERATIONS REVENUE INCREASED 5.6% VS. Q2FY05
>>       YEAR-TO-DATE REVENUES UP 10.1% FROM THE SAME PERIOD LAST YEAR
>>       GROUND BREAKING FOR LAS VEGAS HOSPITAL SCHEDULED FOR MARCH 15, 2006

Peabody, Mass., February 14, 2006 -- PHC, Inc., d.b.a. Pioneer Behavioral Health
(OTC Bulletin  Board:  PIHC),  a leading  provider of inpatient  and  outpatient
behavioral  health  services and  pharmaceutical  research,  today announced its
fiscal 2006 second quarter financial results, for the quarter ended December 31,
2005.

     Total net revenue from operations increased 7.8 percent to $8.7 million for
the three months ended December 31, 2005 compared to $8.1 million for the second
quarter of fiscal 2005.  Net patient care revenue  increased 8.6 percent to $6.5
million from $6.0 million for the second  quarter of fiscal 2005,  due primarily
to the  addition  of the 30  adjudicated  juvenile  beds at  Detroit  Behavioral
Institute,  which  helped  generate a 24.7  percent  increase  in patient  days.
Revenue from  pharmaceutical  studies  decreased 9.2 percent to $1.1 million for
the quarter  compared to $1.2 million for the same  quarter last year.  Contract
support services  revenue  provided by Wellplace  increased 24.9 percent to $1.2
million for the quarter  compared to $923,323  for the same  quarter  last year,
which  resulted  from the October 2004  expansion in  Wellplace's  Michigan call
center  contract and the tobacco  cessation  services which began in November of
2005 for a major government contractor.

Total operating  expenses for the quarter increased 10.3 percent to $8.2 million
from $7.4  million  during the second  quarter  of last year.  Included  in this
increase  was a 44.8  percent  increase  in the  Company's  bad debt  expense to
$475,768  compared to the year-ago  period related to the  previously  announced
technical  issue in the Company's  billing  software at its Harbor Oaks Hospital
facility  during the first  quarter of fiscal  2006.  However,  bad debt expense
decreased  27.6  percent  sequentially  or by  $181,119  compared  to the  first
quarter.  The failure of the  billing  software  during the first  quarter had a
residual effect on the Company's  billing and receipt of collections  during the
second  quarter,  resulting  in an  increase  in  the  aging  of  those  related
receivables  which was  responsible  for an  increase in the  Company's  overall
allowance for doubtful  accounts and bad debt expenses.  With the billing system
properly operating,  management expects the reserve requirement will decrease in
future quarters as collection  activity returns to more normalized  levels.  The
Company expects to collect a significant portion of the receivables in the third
fiscal quarter. Also impacting operating expenses was a 13.7 percent increase in
administrative  expenses,  resulting from increased  administrative  payroll and
employee  benefits directly related to the opening of the new 20-bed unit at the
Detroit Behavioral Institute.

Income from  operations  for the quarter was $549,060 a decrease of 19.2 percent
compared to the $679,895  reported for the same period last year. Cash flow from
operations  for the six months  ended  December  31, 2005 was  $873,743  and the
company  incurred  $627,776  in capital  expenditures  for the six month  period
related to the Company's expansion.

Net income applicable to common  shareholders for the three months was $346,782,
or $0.02 per fully  diluted  share,  compared  to  $408,804,  or $0.02 per fully
diluted share, for the second quarter of fiscal 2005. This was derived utilizing


                                    -- 4 --

19.3 million fully diluted shares  compared to 18.5 million fully diluted shares
for the respective  reporting periods.  The Company's provision for income taxes
decreased to $64,600 with an effective tax rate of 15.7 percent compared to 15.1
percent in the year-ago period.

Bruce A. Shear,  Pioneer's  President and Chief  Executive  Officer,  commented,
"Building off our record  performance last year, the Company continues to report
top-line  growth  and  consistent  profitability.  We are  focused on laying the
foundation for our next growth phase, which will be driven by the opening of our
Seven Hills Medical Complex in Henderson, Nevada, the continued expansion at the
Detroit  Medical Center and further revenue  contributions  from our new smoking
cessation program.  Management has worked diligently to build a foundation which
will  contribute  to solid  operating  results for the balance of the year while
accelerating the momentum into fiscal 2007."

For the first six months of fiscal 2006, the Company  reported  revenue of $17.6
million, an increase of 10.1 percent compared to the $16.0 million for the first
six months of last year.  Net  patient  care  revenues  were $13.2  million,  an
increase of 8.4 percent compared to the $12.2 million reported for the first six
months of last year. Pharmaceutical study revenues increased 4.8 percent to $2.4
million from the $2.3 million  reported for the same period last year.  Contract
support  services  revenue  increased  31.1  percent to $2.1  million  from $1.6
million last year. Total operating  expenses were $16.5 million,  an increase of
14.1  percent  from the $14.5  million for the first six months of fiscal  2005,
including a 94.4  percent  increase in the  Company's  bad debt expense to $1.13
million  due to the  previously  mentioned  software  billing  issue  and a 17.0
percent  increase in  administrative  expenses.  Income from operations was $1.1
million,  a decrease of 26.5 percent  compared to the $1.6 million reported last
year. Net income applicable to common  shareholders for the six-month period was
$730,989  or $0.04 per fully  diluted  share,  compared  with net income of $1.2
million or $0.06 per fully  diluted  share for the same period  last year.  19.3
million and 18.3 million  fully diluted  shares were used to calculate  earnings
per share for the respective periods.

The Company's  balance  sheet  reported a current ratio of 1.6:1 on December 31,
2005.  Shareholders'  equity  increased 9.8 percent to $10.0 million on December
31, 2005 from $9.1 million on June 30, 2005.  The Company  reported $1.0 million
in cash as of  December  31,  2005,  up from  $917,630 on June 30,  2005.  Total
receivables for the second quarter of 2006 were $8.7 million versus $5.9 million
during the comparable period in fiscal 2005. Bad debt expense increased 44.8% to
$475,768  for the  second  quarter  from  $328,638  last  year,  but  were  down
sequentially  from $656,887  recorded  during the first quarter of 2006.  DSO's,
allowance  for doubtful  accounts and bad debt expense all  increased due to the
software  problems which slowed the billing process and diverted staff attention
from  collections,  while we reentered  the  receivables  into the new software.
Since the  Company's  policy  is to  maintain  reserves  based on the age of its
receivables,  this delay in the billing and  collection  process  increased  the
amount and age of the Company's receivables  therefore,  increasing the reserves
required by formula and the bad debt  expense.  The system is now  operating and
management  expects the reserve  requirement will decrease in future quarters as
collection activity has now become more normalized. The Company expects bad debt
expense in the third quarter to be below our previously reported levels.

Mr.  Shear  continued,  "While the  accounts  receivables  balance  reported  on
December 31st were still at elevated levels,  we have made significant  progress
in the  resolution  of the technical  issue which  impacted  collections  at our
largest  inpatient  facility,  and required the  increase in our  allowance  for
doubtful accounts and bad debt expense.  We expect the reserve  requirement will
decrease  in  future  quarters  as  collection  activity  has  now  become  more
normalized  and anticipate bad debt expense in the third quarter to be below our
second quarter reported levels.  The billing platform is operating  properly and
the new software system which will be implemented later this year is expected to
ensure this issue will not reoccur,  while providing incremental benefits to our
organization."

Teleconference Information

The Company  will  conduct a  conference  call to discuss the fiscal 2006 second
quarter  results  on  Tuesday,  February  14,  2006,  at 9  a.m.  Eastern  Time.
Interested  parties  within  the  United  States  can access the call by dialing
866-510-0710,  and  international  callers  may dial  617-597-5378.  Please  use
passcode  10821525.  A replay of the call also will be available  until February
21, 2006 at 888-286-8010 for callers within the United States,  and 617-801-6888
for international  callers.  Please use passcode  99645912 for the replay.  This
call is being  webcast by CCBN,  and can be accessed at PHC,  Inc.'s web site at
www.phc-inc.com.  The webcast is also being  distributed  over  CCBN's  Investor
Distribution Network to both institutional and individual investors.  Individual
investors can listen to the call through CCBN's  individual  investor  center at
www.fulldisclosure.com,  or by  visiting  any of the  investor  sites in  CCBN's


                                    -- 5 --

Individual  Investor  Network.  Institutional  investors can access the call via
CCBN's    password-protected   event   management   site,    StreetEvents,    at
www.streetevents.com.

About Pioneer Behavioral Health

Pioneer   Behavioral  Health  operates  companies  that  provide  inpatient  and
outpatient  behavioral  health care services,  clinical  research,  Internet and
telephonic-based   referral  services.  The  companies  contract  with  national
insurance  companies,  government  payors,  and major  transportation and gaming
companies, among others, to provide such services. For more information,  please
visit www.phc-inc.com or www.haydenir.com.

Statement under the Private Securities Litigation Reform Act of 1995:

This press release may include "forward-looking  statements" that are subject to
risks and uncertainties.  Forward-looking  statements include  information about
possible or assumed future  results of the operations or the  performance of the
company and its future plans and  objectives.  Various  future events or factors
may cause the actual  results to vary  materially  from those  expressed  in any
forward-looking statements made in this press release. For a discussion of these
factors and risks,  see the  company's  annual  report on Form 10-K for the most
recently ended fiscal year.

                                - tables follow -


                                    -- 6 --

       PHC, INC. AND SUBSIDIARIES
                      CONDENSED CONSOLIDATED BALANCE SHEETS

                                                    December 31,     June 30,
                           ASSETS                      2005            2005
                                                    (unaudited)
                                                   _____________    ___________
Current assets:
   Cash and cash equivalents                         $ 1,028,610    $  917,630
   Accounts receivable, net of allowance for
     doubtful accounts of $3,173,004 at December
     31,2005 and $1,956,984 at June 30, 2005           6,673,756     6,265,381
   Pharmaceutical receivables                          1,361,227     1,414,340
   Prepaid expenses                                      496,153       146,988
   Other receivables and advances                        561,959       638,654
   Deferred income tax asset                           1,415,344     1,375,800
                                                     ___________   ____________

       Total current assets                           11,537,049    10,758,793
   Accounts receivable, non-current                       50,000        65,000
   Other receivable                                      120,213        84,422
   Property and equipment, net                         1,901,434     1,516,114
   Deferred financing costs, net of amortization of
     $95,557 at December 31, 2005 and $76,234 June
     30, 2005                                            126,615       145,938
   Customer relationships, net of amortization of
     $200,000 at December 31, 2005 and $140,000 at
     June 30, 2005                                     2,200,000     2,260,000
   Goodwill                                            2,704,389     2,648,209
   Other assets                                          436,317       417,172
                                                     ___________   ____________

       Total assets                                  $19,076,017   $17,895,648
                                                     ===========   ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
   Accounts payable                                  $ 1,857,219    $  907,569
   Current maturities of long-term debt                  843,409       769,599
   Revolving credit note                               2,523,035     2,385,629
   Deferred revenue                                       80,479        85,061
   Current portion of obligations under capital
     leases                                               46,312        29,777
   Accrued payroll, payroll taxes and benefits         1,321,616     1,411,653
   Accrued expenses and other liabilities                601,735     1,063,189
                                                     ___________   ____________
       Total current liabilities                       7,273,805     6,652,477
   Long-term debt                                      1,505,567     1,900,022
   Obligations under capital leases                       55,304        12,210
   Deferred tax liability                                244,874       229,000
                                                     ___________   ____________
  Total liabilities                                    9,079,550     8,793,709
                                                     ___________   ____________

Stockholders' equity:
   Preferred Stock, 1,000,000 shares authorized,
      none issued or outstanding                              --            --
   Class A common stock, $.01 par value,
     30,000,000 shares authorized, 17,603,118 and
     17,490,818 shares issued at December 31, 2005
     and June 30, 2005, respectively                     176,031       174,908
   Class B common stock, $.01 par value, 2,000,000
     shares authorized, 776,991 issued and outstanding
     December 31, 2005 and June 30, 2005 each
     convertible into one share of Class A common
     Stock                                                 7,770         7,770
   Additional paid-in capital                         23,576,088    23,377,059
   Treasury stock, 191,098 shares and 181,738 shares
     of Class A common stock at December 31 and June
     30, respectively, at cost                          (191,700)     (155,087)
Accumulated deficit                                  (13,571,722)  (14,302,711)
                                                     ___________   ____________

Total stockholders' equity                             9,996,467     9,101,939
                                                     ___________   ____________
Total liabilities and stockholders' equity           $19,076,017   $17,895,648
                                                     ===========   ===========

                                    -- 7 --

                           PHC, INC. AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)


                                                                 
                                       Three Months Ended      Six Months Ended
                                           December 31,           December 31,
                                         2005       2004      2005            2004
                                     _____________________    _____________________

Revenues:
     Patient care, net                $6,465,356  $5,951,326  $13,178,336  $12,160,825
     Pharmaceutical studies            1,084,084   1,194,552    2,390,093    2,281,142
     Contract support services         1,153,073     923,323    2,078,910    1,584,749
                                       __________  __________   __________   __________
          Total revenues               8,702,513   8,069,201   17,647,339   16,026,716
                                       __________  __________   __________   __________
Operating expenses:
     Patient care expenses             3,292,393   2,967,320    6,554,304    6,008,302
     Patient care expenses,
       pharmaceutical                    510,834     412,144    1,073,988      802,107
     Cost of contract support services   587,067     558,094    1,184,862    1,075,003
     Provision for doubtful accounts     475,768     328,638    1,132,655      582,747
     Administrative expenses           2,749,100   2,418,501    5,378,776    4,598,162
     Administrative expenses,
       pharmaceutical                    538,291     704,609    1,172,290    1,395,665
                                       __________  __________   __________   __________
          Total operating expenses     8,153,453   7,389,306   16,496,875   14,461,986
                                       __________  __________   __________   __________
Income from operations                   549,060     679,895    1,150,464    1,564,730
                                       __________  __________   __________   __________
     Other income (expense):
      Interest income                     15,397      17,492       38,261       34,531
      Other income                        21,263      13,683       32,048       26,492
      Interest expense                  (174,338)   (229,797)    (329,556)    (342,852)
                                       __________  __________   __________   __________
          Total other expenses, net     (137,678)   (198,622)    (259,247)    (281,829)
                                       __________  __________   __________   __________

Income before provision for taxes        411,382     481,273      891,217    1,282,901
Provision for income taxes                64,600      72,469      160,228       98,469
                                       __________  __________   __________   __________

Net income                              $346,782    $408,804     $730,989   $1,184,432
                                       ==========  ==========   ==========   ==========

Basic net income per common share       $   0.02    $   0.02      $  0.04   $     0.07
                                        ==========  ==========   ==========   ==========

Basic weighted average number of
   shares Outstanding                 18,159,188  17,417,238   18,125,265   17,388,921
                                      ==========  ==========   ==========   ==========
Fully diluted net income per
   common share                       $     0.02    $   0.02      $  0.04    $   0.06
                                      ==========  ==========   ==========   ==========

Fully diluted weighted average
   number of shares outstanding       19,301,486  18,471,375   19,302,592   18,274,631
                                      ==========  ==========   ==========   ==========





                                    -- 8 --